G6PD Deficiency Inheritance and Testing: What the WHO Classification and Two Major Reviews of 400 Million Cases Actually Show

G6PD Deficiency Inheritance and Testing: What the WHO Classification and Two Major Reviews of 400 Million Cases Actually Show

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

Bottom line: Two major reviews in The Lancet and the New England Journal of Medicine agree that G6PD deficiency is the most common human enzyme defect, affecting an estimated 400 million people worldwide. It is X-linked, so a father passes his variant to every daughter but no son. Most people stay symptom-free for life and manage it by avoiding a few triggers. A consumer report is a screening flag, not a diagnosis; confirmatory testing runs through a physician.

What you’ll learn:

• How the X-linked pattern decides which of your children can inherit the variant, with concrete percentages.
• Why a 23andMe note is only a screening flag, and how a real diagnosis is confirmed.
• Which drugs the FDA legally requires G6PD testing before use, and why.
• How GINA and Canada’s genetic-privacy law protect you, and the one insurance gap they leave open.

How G6PD deficiency is inherited: the X-linked recessive pattern

G6PD deficiency comes from changes in the G6PD gene. That gene sits on the X chromosome at a spot called Xq28. The gene’s normal job is to make an enzyme that protects red blood cells from oxidative damage. When the enzyme is in short supply, red cells become fragile under stress. The condition follows X-linked recessive inheritance. In plain terms, that means the risky gene copy lives on the X chromosome and usually needs to act without a healthy backup copy.

This is where sex matters. Males have one X and one Y chromosome. So a male with one variant copy has no backup, and he is usually affected (doctors call this “hemizygous”). This is why the condition is more often symptomatic in males than in females. Females have two X chromosomes. A female with one variant copy is usually a carrier, because her second, healthy X often covers for it. A female is typically fully affected only if she inherits two variant copies, one from each parent, or shows skewed X-inactivation. Some carrier women still show symptoms anyway, and the reason is explained below.

Think of the X chromosome as a spare key. Males carry only one key, so a bad key locks them out. Females carry two, so a good spare usually still opens the door.

Here is how it plays out in a real family:

Parent who carries the variant	Sons	Daughters
Affected father	0% inherit it (he gives them his Y)	100% become carriers (he gives them his X)
Carrier mother	50% chance affected	50% chance carrier

So an affected father passes the variant to all of his daughters as carriers, but to none of his sons. A carrier mother has a 50% chance of passing it to each child, whatever their sex. Two sons of the same carrier mother can end up different: one affected, one not, since each pregnancy is an independent coin flip.

It also helps to know where the change actually happens. The molecular label for the disorder is OMIM #305900, and researchers have catalogued many distinct variants of the same gene. That catalog is why one family’s variant may be milder than another’s, even though both are “G6PD deficiency.” If your family history is confusing, a primary care doctor or a genetic counselor (find one at NSGC.org) can map it out with you.

Section recap: The variant sits on the X chromosome, so males with one copy are usually affected while females are usually carriers. An affected father passes it to every daughter but no son.

Prevalence, ancestry, and why risk varies by heritage

G6PD deficiency is not rare. It is the most common enzyme defect in humans, affecting an estimated 400 million people worldwide. To make that concrete, that is roughly 5 out of every 100 people on the planet, though the rate is far higher in some regions and near zero in others.

Why the uneven spread? The variant is more common in people with African, Mediterranean, Middle Eastern, or Southeast Asian ancestry. Research links this pattern to regions where malaria was historically common. The same red-cell change that causes deficiency also offers some protection against malaria. Over many generations, that survival advantage kept the variant frequent in those populations. It is a striking example of how a “disease gene” can persist because it once helped people survive a deadly infection.

Not all variants behave the same. Two common ones illustrate the range:

• G6PD A- (African origin): usually milder, with more enzyme activity left over.
• G6PD Mediterranean (c.563C>T): more severe, with lower enzyme activity and stronger hemolysis.

These are not just labels. The FDA drug labels that require G6PD screening single out people of African or Mediterranean ancestry as higher-risk groups. That is a concrete example of ancestry guiding real clinical decisions. A few variants are severe enough to cause chronic hemolytic anemia even without any outside trigger, though these are far less common than the trigger-dependent forms.

Ancestry raises the prior odds, but it is only a starting point. It does not equal a diagnosis. Many people of high-risk heritage do not carry the variant, and some people with no known high-risk background do. Only a test can confirm your status. Your primary care physician can order that test if your background suggests it, and a genetic counselor can explain what your specific variant means.

Section recap: About 400 million people are affected, with higher rates in African, Mediterranean, Middle Eastern, and Southeast Asian ancestry linked to historic malaria regions. Heritage raises the odds but never replaces a test.

Recognizing a hemolytic crisis: triggers and warning signs

The central risk in G6PD deficiency is acute hemolytic anemia. That means red blood cells break apart faster than the body can replace them. It usually starts 24 to 72 hours after exposure to a trigger. Knowing the signs helps you act fast, because early recognition can be the difference between a mild episode and a hospital visit.

Watch for these warning signs:

• Dark or cola-colored urine
• Yellowing of the skin or eyes (jaundice)
• Paleness and unusual tiredness
• A fast or pounding heartbeat

Three trigger categories are well documented in the research:

1. Fava beans. Eating them can set off hemolysis, a reaction called favism, because compounds in the beans (vicine and convicine) generate cell-damaging free radicals in deficient red cells. This is such a classic pattern that the whole condition is sometimes called “favism.”
2. Specific drugs. These include primaquine and related antimalarials (the “8-aminoquinolines”), sulfonamides, dapsone, nitrofurantoin, rasburicase, and methylene blue. Some of these are covered in detail in the prevention section below.
3. Infections. A common cold or stomach bug can trigger a crisis on its own, with no drug or food involved. This is easy to overlook because the infection itself, not a medicine, is the culprit.

Newborn jaundice is a separate presentation that shows up shortly after birth. It is one of the two main clinical faces of the condition, alongside trigger-related hemolysis. In a newborn, jaundice can appear or worsen faster than usual, which is why some hospitals watch at-risk babies closely. If a baby in a G6PD family looks yellow or is unusually sleepy, that is a reason to call the pediatrician promptly.

To grade how severe a variant is, the WHO reclassified variants in 2022 by residual enzyme activity. The old 1985 scheme used classes I to V. The new one uses four classes:

• Class A: the most severely deficient (under 20% activity), linked to chronic hemolysis even without a trigger.
• Class B: the common deficient variants, including G6PD Mediterranean and G6PD A-.
• Class C: non-deficient, normal activity (over 60%).
• Class U: uncertain, a temporary label for newly found variants until activity can be measured reliably.

The key shift is that severity is now graded by actual enzyme numbers, not by older clinical descriptions. Think of a trigger as a match and low enzyme activity as dry kindling: the less enzyme, the faster it catches. If you notice dark urine or jaundice after a trigger, seek urgent care and tell the clinician about your G6PD status.

Section recap: A crisis appears 24 to 72 hours after fava beans, certain drugs, or an infection, with dark urine, jaundice, pallor, and fatigue. The WHO now grades severity by leftover enzyme activity.

Testing options: diagnostic enzyme assay vs DTC genetic reports

There are two very different ways to learn about your G6PD status, and confusing them is a common mistake. One gives you a medical diagnosis. The other gives you a hint that a diagnosis might be worth pursuing. Treating the second as if it were the first is where people go wrong.

The clinical gold standard is a quantitative G6PD enzyme activity assay, often confirmed with genotyping. In plain terms, it measures how much working enzyme your red cells actually have, rather than guessing from a single DNA spot. A physician orders it, and it is typically covered by insurance in the US or by provincial health plans in Canada.

Direct-to-consumer (DTC) reports are a different tool:

Feature	Physician-ordered enzyme assay	DTC report (e.g., 23andMe)
Purpose	Diagnosis	Screening flag only
Scope	Measures actual enzyme activity	Checks a few pre-selected variants
A negative result means	Deficiency is unlikely	Deficiency is not ruled out
Ordered by	A clinician	The consumer

The FDA authorizes some 23andMe Genetic Health Risk reports as screening tools, not diagnostic tests, and requires labeling that says results should be confirmed clinically. These reports usually check only a few pre-selected variants rather than reading the whole gene. That is why a “variant not detected” result does not rule out G6PD deficiency. Broader carrier panels through services like Color or Invitae can test more variants, but even these do not replace a diagnostic assay. FDA guidance is explicit that consumer genetic results should not drive treatment decisions without confirmatory testing and a healthcare provider’s input.

One critical pitfall deserves its own spotlight, because it trips up patients and clinicians alike. Testing during an acute crisis can read falsely normal. Here is why: older red cells are destroyed first in a crisis, and the young cells left behind (called reticulocytes) naturally carry higher enzyme activity. So a test taken mid-crisis samples the “best” cells and can miss the deficiency. For that reason, testing should be repeated 2 to 3 months after recovery, once the red-cell population is back to baseline.

Newborn screening adds another wrinkle. It is offered in some but not all US states and Canadian provinces. So a “normal” newborn screen is only reassuring if your area actually screens for G6PD, which is worth confirming with your pediatrician. If a consumer report flags G6PD, ask your physician about a confirmatory quantitative assay.

Section recap: A physician-ordered quantitative enzyme assay diagnoses G6PD deficiency, while a DTC report only screens. Testing during a crisis can be falsely normal, so it should be repeated after recovery.

Interpreting your result: diagnosis, carrier status, and uncertainty

A test result is only useful if you know what it does and does not say. Two people can hold the same paper result and face very different realities. An affected male typically shows low enzyme activity and a clinically relevant deficiency. His path is usually straightforward: confirm, then avoid triggers. A female carrier is more complicated: her enzyme activity can be intermediate, and she may still experience hemolysis. Her result needs more careful interpretation, ideally with a clinician who can weigh her activity level against her family history.

Why the difference in women? Each cell randomly switches off one of its two X chromosomes, a process called X-inactivation. If more cells happen to silence the healthy X, a carrier woman can behave much like an affected person. So yes, a woman can have clinically significant G6PD deficiency, not just carrier status.

This has a practical testing consequence. A carrier woman’s enzyme activity can fall in an intermediate range. Older, simpler screening tests (the “fluorescent spot” test) can miss her entirely. A quantitative assay is more reliable for detecting carriers, which is one more reason the type of test matters.

To keep interpretation consistent, geneticists use a shared framework from the ACMG and AMP. It sorts genetic findings into five categories:

• Pathogenic: a confirmed disease-causing variant.
• Likely pathogenic: strong but not definitive evidence it causes disease.
• Variant of uncertain significance (VUS): it neither confirms nor rules out disease and should not by itself drive care.
• Likely benign: probably harmless.
• Benign: harmless.

That middle category, the VUS, causes the most confusion. A VUS is not a diagnosis and is not a clean bill of health; it simply means the evidence is not yet clear. Actionable results generally call for confirmatory clinical testing and interpretation by qualified professionals.

A 23andMe note is a screening flag, not a diagnosis. DTC reports check only a limited set of variants, so they can miss rarer pathogenic changes or a VUS. The right next step is confirmatory quantitative testing ordered through a physician, and a genetic counselor can help interpret an unclear result.

Section recap: Affected males show low enzyme activity, while carrier females vary because of X-inactivation and can still hemolyze. A consumer flag is not a diagnosis; confirmatory clinical testing is the correct next step.

Prevention and daily management: an evidence-based avoidance strategy

For most people, managing G6PD deficiency means avoiding triggers, not taking a treatment. That is because most affected people stay symptom-free between crises and have a normal life expectancy. The goal is steady prevention, not constant worry.

This framing matters because it changes how you think about the condition. It is not a chronic illness you treat every day. It is a fixed sensitivity you plan around, much like an allergy. A practical daily plan looks like this:

• Tell every prescriber and pharmacist about your G6PD status, and keep an updated medication list.
• Avoid fava beans and foods that contain them.
• Treat infections promptly, since infection alone can trigger a crisis.
• Monitor newborns for jaundice, which can appear soon after birth.
• Carry your status where it will be seen, such as a phone medical ID or a wallet card.

Some drugs legally require G6PD testing or are off-limits, and the FDA labeling is explicit. These are not general cautions; they are formal warnings and contraindications tied to specific drugs:

• Rasburicase (Elitek) carries a boxed warning, the FDA’s strongest, contraindicating use in G6PD deficiency. High-risk patients should be screened first, and the drug must be stopped permanently if hemolysis occurs (FDA approved 2002).
• Pegloticase (Krystexxa) is contraindicated in G6PD deficiency, and at-risk patients should be screened before use (FDA approved 2010). It should not be given to anyone with a documented deficiency.
• Tafenoquine (Krintafel / Arakoda) requires documented normal G6PD before administration and is contraindicated in deficiency or unknown status (FDA approved 2018). Patients should be monitored for hemolysis after they take it.

Health Canada carries parallel safety guidance for these agents, so the requirement holds on both sides of the border.

The reason these drugs are so strictly labeled is the same chemistry behind favism. Rasburicase and pegloticase both break down uric acid and produce hydrogen peroxide as a byproduct. In G6PD-deficient red cells, that peroxide causes oxidative damage and hemolysis. Tafenoquine causes irreversible oxidative damage to red cells in deficient patients, which is why a documented normal G6PD result is required before it is given. These are not cautious suggestions; they are contraindications written into the label.

Think of your G6PD status like a food allergy card: the more consistently you share it, the safer every prescription becomes. Severe hemolysis can require a blood transfusion and urgent care, so do not wait out serious symptoms. It is worth noting that evidence keeps evolving on which drugs are truly unsafe versus historically over-restricted, so an up-to-date clinician judgment beats an old printed list. When in doubt about a new medication, ask your physician or pharmacist to check it against your status.

Section recap: Management is trigger avoidance: disclose your status, skip fava beans, treat infections early, and watch newborns. The FDA requires G6PD testing before rasburicase, pegloticase, and tafenoquine.

Family implications: cascade testing and talking to relatives

When one family member is confirmed, relatives benefit from knowing too. This step-by-step screening of at-risk relatives is called cascade testing. It lets family members avoid dangerous triggers before a crisis ever happens.

X-linked inheritance shapes who to test first:

• Male relatives on the maternal line, who are most likely to be affected.
• Daughters of an affected father, who are obligate carriers.
• Siblings of an affected person, depending on which parent carries the variant.

There is a real payoff to acting early. Because the risk is trigger-driven, a relative who knows their status can simply avoid fava beans and flag their status before any prescription. That turns a potential emergency into a non-event. For a newborn in the family, knowing a parent’s status can prompt closer monitoring for jaundice.

How you frame the conversation matters as much as the biology. It can help to lead with the practical benefit: knowing lets a relative avoid a specific medication or food, not just receive a label. Genetic counseling also supports the emotional side, helping families make informed choices and talk through inherited risk without blame. For a large or complicated family tree, an NSGC-certified genetic counselor can coordinate testing and interpret results across relatives. You can find one through the NSGC directory. Framing it as shared safety, rather than blame, tends to keep the conversation open.

Section recap: Cascade testing screens at-risk relatives, prioritizing maternal-line males and daughters of affected fathers. A genetic counselor can coordinate testing and help families frame the conversation.

Privacy, insurance, and psychosocial impact in the US and Canada

Many people worry a genetic result could be used against them, and that worry is one reason some avoid testing at all. The law offers real, though incomplete, protection, and understanding it can remove a barrier to getting properly tested. In the US, the Genetic Information Nondiscrimination Act (GINA), enacted in 2008, bars health insurers and employers from discriminating based on genetic information. That means a health plan cannot deny you or charge you more because of a G6PD result, and an employer cannot use it in hiring or firing. The Affordable Care Act (ACA) separately prohibits denying coverage or charging more for pre-existing conditions.

But GINA has a well-known gap. It does not cover life, disability, or long-term-care insurance. So while your employer and health plan cannot use a G6PD result against you, an insurer selling one of those other products legally can consider genetic information in some cases. For a mostly benign, manageable condition like G6PD deficiency, this gap is worth knowing but rarely a practical barrier. Still, knowing it helps you make informed choices before you test.

Canada takes a broader approach. The Genetic Non-Discrimination Act (2017) prohibits requiring or using genetic test results as a condition of goods, services, or contracts. That wording is wide enough to reach insurance contracts, not just employment. The Supreme Court of Canada upheld the law’s constitutionality in 2020, so it stands on firm legal ground. Here is a quick comparison:

Protection	United States	Canada
Health insurance	Protected (GINA + ACA)	Protected
Employment	Protected (GINA)	Protected
Life / disability insurance	Not covered by GINA	Broadly protected

One point deserves emphasis before testing: think through the insurance angle in advance. Because GINA leaves life and disability coverage uncovered, some people choose to sort out those policies before adding a documented result to their records. A genetic counselor can walk you through these trade-offs without pushing you either way.

On the emotional side, it helps to keep perspective. G6PD deficiency is usually a well-managed condition with a normal life expectancy. The main risks are anxiety and over-restricting diet or activity beyond what the evidence supports. Parents, in particular, can drift into fear-driven rules that shrink a child’s daily life without real benefit. Turning every meal into a worry is its own harm, and the evidence does not support blanket restriction. The realistic picture is a normal life with a short list of things to avoid, not a life of constant vigilance. A genetic counselor can address these concerns and support informed decisions. If a diagnosis is weighing on you or your family, talk it through with a counselor or your physician rather than carrying it alone.

Section recap: GINA and the ACA protect US health insurance and employment but not life or disability insurance, while Canada’s law is broader. The condition is usually well managed, and counseling helps reduce undue fear.

Frequently asked questions

Will I get the disease? Having the variant does not mean you will have symptoms. Many carriers and even affected people stay well for life as long as they avoid triggers. In fact, most affected people are symptom-free between crises and have a normal life expectancy. Whether you have the deficiency at all depends on your sex and your specific variant, which only a quantitative enzyme test can confirm. Your physician can order that test.

Will my children inherit it? It depends on who carries the variant. An affected father passes it to all of his daughters as carriers but to none of his sons. A carrier mother has a 50% chance of passing it to each child, whichever their sex. Because each pregnancy is independent, past outcomes do not change the odds for the next child. A genetic counselor can map your family’s specific odds (NSGC.org).

Will this affect my health or life insurance? In the US, GINA and the ACA protect your health insurance from genetic discrimination. But GINA does not cover life, disability, or long-term-care insurance. In Canada, the Genetic Non-Discrimination Act offers broader protection. Consider this before testing, and ask a counselor if you are unsure.

Can my employer find out? In the US, GINA prohibits employers from using your genetic information against you. Canada’s Genetic Non-Discrimination Act similarly bars using genetic test results as a condition of employment or services. If you have concerns, a genetic counselor can walk you through your rights.

Can a woman be affected, or only be a carrier? A woman can be genuinely affected, not just a carrier. Because of X-inactivation, some carrier women silence enough of their healthy X copies to show low enzyme activity and real hemolysis. Simpler screening tests can miss these carriers, so a quantitative assay is more reliable. If you are a woman with a family history, ask your physician about quantitative testing.

Should I get a second opinion? Yes, especially if your only result is a DTC screening flag. A consumer report is not a diagnosis, and confirmatory quantitative testing through a physician is the appropriate next step. A board-certified genetic counselor can review your result and coordinate further testing. A second opinion is also reasonable if a variant of uncertain significance leaves you unsure what to do.

Summary

G6PD deficiency is the most common human enzyme defect, affecting an estimated 400 million people worldwide. It is X-linked, so an affected father passes the variant to every daughter but no son, while a carrier mother has a 50% chance per child. Ancestry from historically malaria-endemic regions raises the odds but never replaces a test.

The practical core is simple: most affected people stay well by avoiding fava beans, certain drugs, and untreated infections. A crisis, when it happens, tends to arrive 24 to 72 hours after a trigger, with dark urine, jaundice, and fatigue as the warning signs. The FDA legally requires G6PD testing before rasburicase, pegloticase, and tafenoquine, and Health Canada mirrors that guidance. A 23andMe note is a screening flag, not a diagnosis, and confirmatory quantitative testing runs through a physician. Remember that testing during a crisis can read falsely normal, so it may need repeating after recovery.

Finally, GINA and Canada’s genetic-privacy law protect you, though the US life-insurance gap remains. The overall message is reassuring: this is a common, well-understood condition that most people manage with a short list of precautions and a normal life expectancy. For your own situation, work with a physician and an NSGC-certified genetic counselor.

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

References

1. MedlinePlus Genetics, NIH/NLM (reviewed 2023). Glucose-6-phosphate dehydrogenase deficiency. Tier 1. https://medlineplus.gov/genetics/condition/glucose-6-phosphate-dehydrogenase-deficiency/
2. NIH GARD (Genetic and Rare Diseases Information Center). Glucose-6-phosphate dehydrogenase deficiency. Tier 1. https://rarediseases.info.nih.gov/diseases/6520/glucose-6-phosphate-dehydrogenase-deficiency
3. Cappellini MD & Fiorelli G (2008). Glucose-6-phosphate dehydrogenase deficiency. The Lancet 371(9606):64-74. Tier 1. https://pubmed.ncbi.nlm.nih.gov/18177777/
4. Luzzatto L & Arese P (2018). Favism and Glucose-6-Phosphate Dehydrogenase Deficiency. New England Journal of Medicine 378(1):60-71. Tier 1. https://pubmed.ncbi.nlm.nih.gov/29298156/
5. Luzzatto L et al. (2023). Genetic variants causing G6PD deficiency: WHO 2022 classification. British Journal of Haematology 201(6):1027-1030. Tier 2. https://onlinelibrary.wiley.com/doi/10.1111/bjh.18943
6. FDA drug label — Elitek (rasburicase), Sanofi. Boxed warning: hemolysis in G6PD deficiency (FDA approved 2002). Tier 1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/103946s5171lbl.pdf
7. FDA drug label — Krystexxa (pegloticase), Horizon/Amgen. Contraindicated in G6PD deficiency (FDA approved 2010). Tier 1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125293s0000lbl.pdf
8. FDA drug label — Krintafel / Arakoda (tafenoquine), GSK / 60 Degrees Pharmaceuticals. G6PD testing required before administration (FDA approved 2018). Tier 1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cf989d5-36f5-4561-a30b-9fcb9deb6b6a
9. GeneReviews / StatPearls (University of Washington / NCBI Bookshelf). Glucose-6-Phosphate Dehydrogenase Deficiency. Tier 2. https://www.ncbi.nlm.nih.gov/books/NBK470315/
10. Richards S et al. (2015). Standards and guidelines for the interpretation of sequence variants (ACMG/AMP). Genetics in Medicine 17(5):405-424. Tier 2. https://pubmed.ncbi.nlm.nih.gov/25741868/
11. OMIM #305900, Johns Hopkins University / NCBI. Hemolytic anemia due to G6PD deficiency. Tier 1. https://www.omim.org/entry/305900
12. U.S. FDA. Direct-to-Consumer Tests / Genetic Health Risk authorizations. Tier 1. https://www.fda.gov/medical-devices/vitro-diagnostics/direct-consumer-tests
13. NSGC (National Society of Genetic Counselors). Practice guidance on genetic counseling and cascade testing. Tier 2. https://www.nsgc.org/
14. U.S. EEOC / GINA (2008); Genetic Non-Discrimination Act, Canada (2017). Genetic privacy protections. Tier 1. https://www.eeoc.gov/genetic-information-discrimination

Last updated: 2026-07-16

Author: genelumen editorial team. This article aggregates 14 sources from peer-reviewed medical literature and public health agencies (tier 1=10 / tier 2=4), including NIH, CDC, Health Canada, ACMG guidelines, and PubMed-indexed publications. Editor: Yu Mizuno (水野 悠), non-physician research editor.

This article is for educational purposes only and is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911 (US/Canada) or 119 (Japan).

Related: Genetic Diseases category

🇯🇵 For readers in Japan — a separate Japanese edition written for Japan’s healthcare system (not a translation): https://genelumen.com/ja/ja-metabolic-hematologic-genetic/g6pd-deficiency-x-linked-hemolysis-japan